HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- (9- fluoro- 2- (piperidin- 1- ylcarbonyl)- 1,2,3,4- tetrahydro(1,4)diazepino(6,7,1- hi)indol- 7- yl)- 4- imidazo(1,2- a)pyridin- 3- yl- 1H- pyrrole- 2,5- dione

structure in first source

Also Known As:

LY2090314

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - Maleimides: 16
        3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione: 7
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - 3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione: 7
Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Dicarboxylic Acids: 108
      - Maleates: 3
        Maleimides: 16
        3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione: 7
- Imides: 79
  - Maleimides: 16
    - 3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione: 7

Experts

1.	Boschi, Federico: 1 article (01/2020)
2.	Cavallini, Chiara: 1 article (01/2020)
3.	Melisi, Davide: 1 article (01/2020)
4.	Merz, Valeria: 1 article (01/2020)
5.	Piro, Geny: 1 article (01/2020)
6.	Sabbadini, Fabio: 1 article (01/2020)
7.	Santoro, Raffaela: 1 article (01/2020)
8.	Scarpa, Aldo: 1 article (01/2020)
9.	Simionato, Francesca: 1 article (01/2020)
10.	Zanotto, Marco: 1 article (01/2020)

Related Diseases

1.	Hematologic Neoplasms (Hematological Malignancy) 12/01/2019 - "The pharmacological modulators of GSK-3 such as ABT-869, 6-Bromoindirubin-3'-oxime (BIO), GS-87 and LY2090314 have shown promise in the treatment of hematological malignancy. "
2.	Leukemia 01/01/2016 - "An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia."
3.	Neoplasms (Cancer) 01/01/2015 - "We further demonstrate that in vivo, LY2090314 elevates Axin2 gene expression after a single dose and produces tumor growth delay in A375 melanoma xenografts with repeat dosing. " 03/29/2018 - "In vitro experiments also showed that the LSD1 inhibitor SP2509 and the GSK3β inhibitor LY2090314 acted synergistically to induce cancer cell death. "
4.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2020 - "LY2090314 is a novel agent that warrants further clinical development in combination with nab-paclitaxel for the treatment of pancreatic cancer."
5.	Neuroblastoma 05/11/2018 - "Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro."

Related Drugs and Biologics

1.	Glycogen Synthase Kinase 3
2.	linifanib
3.	6-bromoindirubin-3'-oxime
4.	Glycogen Synthase (Synthase I)
5.	Catenins
6.	Caspases
7.	tideglusib
8.	130-nm albumin-bound paclitaxel
9.	Chir 99021
10.	SB 216763